Drug Profile


Alternative Names: dFdC; dFdCTP; Gemtro; Gemzar; LY 188011

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly; Genentech; University of Innsbruck
  • Developer Cancer Research UK; Eli Lilly; Genentech; Mayo Clinic; National Cancer Institute (USA); University of Iowa
  • Class Antineoplastics; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Biliary cancer; Bladder cancer; Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
  • Phase III Cervical cancer
  • Phase II Lymphoma; Renal cell carcinoma; Salivary gland cancer
  • Phase I/II Sarcoma
  • Phase I Head and neck cancer; Solid tumours

Most Recent Events

  • 22 Aug 2017 Genentech completes a phase I/II trial in Sarcoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, First-line therapy, Second-line therapy or greater, In adults, In the elderly) in USA (unspecified route) (NCT01106872)
  • 13 Jun 2017 Roche plans a phase II/III trial for Non-small cell lung cancer(Monotherapy, Combination therapy, Inoperable/unresectable, Metastatic disease, Late-stage disease) in USA, Australia, Belgium, Brazil, Canada, France, Hong Kong, Italy, South Korea, Mexico, Poland, Spain and Thailand (NCT03178552)
  • 16 Feb 2017 Chonnam National University Hospital and Bayer plan a phase I/II trial for Peripheral T-cell or NK/T-cell lymphoma in South Korea (NCT03052933)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top